414
H.-L. Zhao et al. / Chinese Chemical Letters 25 (2014) 411–414
[6] S.F. Cui, Y. Wang, J.S. Lu, G.L.V. Damu, C.H. Zhou, Recent advances in application of
[16] T. Fuchigami, T. Nonaka, Facile synthesis of 5-acyl-4-amino-2-ethoxythiazoles
from an [ethoxy(thiocarbonyl)]cyanamide salt and a-halo ketones, J. Org. Chem.
48 (1983) 3340–3341.
[17] T. Fuchigami, M.Y. Yeh, T. Nonaka, H.J. Tien, Studies of cyanamide derivatives. Part
109. A convenient method for preparation of 4-aminothiazole compounds from
alkoxythiocarbonylcyanamide salts, Bull. Chem. Soc. Jpn. 56 (1983) 3851–3852.
[18] P. van der Peet, C.T. Gannon, I. Walker, et al., Use of click chemistry to define the
substrate specificity of leishmania b-1,2-mannosyltransferases, ChemBioChem 7
(2006) 1384–1391.
[19] Y. Jin, Z.Y. Zhou, W. Tian, Q. Yu, Y.Q. Long, 40-Alkoxyl substitution enhancing the
anti-mitotic effect of 5-(30,40,50-substituted)anilino-4-hydroxy-8-nitroquinazo-
lines as a novel class of anti-microtubule agents, Bioorg. Med. Chem. Lett. 16
(2006) 5864–5869.
[20] D. Wobig, Thiazolderivate, III. Reaktionen von cyanimidodithiocarbonaten mit a-
chloracetamiden, Liebigs Ann. Chem. 1977 (1977) 400–406.
thiazole compounds, Sci. China: Chem. 42 (2012) 1105–1131.
[7] U. Galm, E. Wendt-Pienkowski, L.Y. Wang, et al., Comparative analysis of the
biosynthetic gene clusters and pathways for three structurally related antitu-
mor antibiotics bleomycin, tallysomycin and zorbamycin, J. Nat. Prod. 74 (2011)
526–536.
[8] J. Zhong, Muscarine, imidazole, oxazole, and thiazole alkaloids, Nat. Prod. Rep. 20
(2003) 584–605.
[9] S. Carradori, D. Secci, A. Bolasco, et al., Synthesis and cytotoxicity of novel (thiazol-
2-yl)hydrazine derivatives as promising anti-Candida agents, Eur. J. Med. Chem.
65 (2013) 102–111.
[10] Y.J. Yang, Y.N. Yang, J.S. Jiang, et al., Synthesis and cytotoxic activity of heterocy-
cle-substituted phthalimide derivatives, Chin. Chem. Lett. 21 (2010) 902–904.
[11] J.D. Moore, A. Potter, Pin1 inhibitors: pitfalls, progress and cellular pharmacology,
Bioorg. Med. Chem. Lett. 23 (2013) 4283–4291.
[12] Y.Y. Xi, J. Jin, Y. Sun, et al., Design, synthesis and biological evaluation of novel
diaryl ethers bearing a pyrimidine motif as human Pin1 inhibitors, Acta Pharm.
Sin. 48 (2013) 1266–1272.
[13] C. Liu, J. Jin, L. Chen, et al., Synthesis and biological evaluation of novel human Pin1
inhibitors with benzophenone skeleton, Bioorg. Med. Chem. 20 (2012) 2992–2999.
[14] L.N. Zhu, J. Jin, C. Liu, et al., Synthesis and biological evaluation of novel quinazo-
line-derived human Pin1 inhibitors, Bioorg. Med. Chem. 19 (2011) 2797–2807.
[15] C.J. Zhang, Z.H. Zhang, B.L. Xu, Y.L. Wang, Recent advances in the study of Pinl and
its inhibitors, Acta Pharm. Sin. 43 (2008) 9–17.
[21] The synthetic procedure and structure identification for compounds 2a–j, 4a–i
and 4k–r are available in Supporting information. All synthesized final products
were characterized by 1H NMR, 13C NMR and ESI-HRMS. For example, compound
4a: light yellow solid; mp 179–182 8C; 1H NMR (300 MHz, DMSO-d6): d 10.77 (s,
1H), 8.27 (s, 1H), 7.79–7.89 (m, 3H), 7.58 (dd, 1H, J1 = 8.7 Hz, J2 = 2.1 Hz), 7.48 (t,
1H, J = 6.9 Hz), 7.38 (t, 1H, J = 7.2 Hz), 6.95 (brs, 2H), 4.14 (q, 2H, J = 6.9 Hz), 1.22 (t,
3H, J = 6.9 Hz); 13C NMR (100 MHz, DMSO-d6): d 165.04, 163.47, 137.56, 133.60,
129.41, 128.73, 127.53, 127.02, 126.61, 124.44, 119.59, 113.80, 58.97, 14.65;
HRMS (ESI) Calcd. for C16H16N3O2S [M+H+]: 314.0958; found: 314.0957.